WRB or CINF: Which P&C Stock Should You Buy for Higher Returns?
https://www.zacks.com/stock/news/2208449/wrb-or-cinf-which-p-c-stock-should-you-buy-for-higher-returns?cid=CS-ZC-FT-analyst_blog|comparison_of_stocks-2208449
Jan 10, 2024 - Let's see how W.R. Berkley (WRB) and Cincinnati Financial (CINF) fare in terms of some of the key metrics.
0
Wall Street Awaits Key Inflation Data
https://www.zacks.com/stock/news/2208354/wall-street-awaits-key-inflation-data?cid=CS-ZC-FT-economic_highlights-2208354
Jan 10, 2024 - Wall Street Awaits Key Inflation Data
0
U.S. Bancorp (USB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://www.zacks.com/stock/news/2208317/u-s-bancorp-usb-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2208317
Jan 10, 2024 - U.S. Bancorp (USB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Quiet Before the Economic Data Storm
https://www.zacks.com/stock/news/2208325/quiet-before-the-economic-data-storm?cid=CS-ZC-FT-ahead_of_wall_street-2208325
Jan 10, 2024 - Among big news on deck this week are CPI and PPI data, Weekly Jobless Claims and the start of Q4 earnings season.
0
Here Is Why Bargain Hunters Would Love Fast-paced Mover Citigroup (C)
https://www.zacks.com/stock/news/2208158/here-is-why-bargain-hunters-would-love-fast-paced-mover-citigroup-c?cid=CS-ZC-FT-tale_of_the_tape|fast_paced_momentum_at_a_bargain-2208158
Jan 10, 2024 - Citigroup (C) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
0
Atea gains after mid-stage data for lead asset in Hepatitis C
https://seekingalpha.com/news/4053570-atea-stock-gains-data-hepatitis-c-drug?source=feed_sector_healthcare
Jan 09, 2024 - Atea Pharmaceuticals (AVIR) stock gains as company's lead asset bemnifosbuvir, shows promising results in a mid-stage trial for Hepatitis C. Read more here.
0
Wall Street Waits for Key Inflation Data
https://www.zacks.com/stock/news/2207063/wall-street-waits-for-key-inflation-data?cid=CS-ZC-FT-economic_highlights-2207063
Jan 08, 2024 - Wall Street Waits for Key Inflation Data.
0
Citigroup (C) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2206564/citigroup-c-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2206564
Jan 05, 2024 - Citigroup (C) reachead $54.33 at the closing of the latest trading day, reflecting a +1.04% change compared to its last close.
0
Soft Loan Demand, High Cost to Ail Citigroup's (C) Q4 Earnings
https://www.zacks.com/stock/news/2206533/soft-loan-demand-high-cost-to-ail-citigroup-s-c-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2206533
Jan 05, 2024 - Waning loan demand is likely to have hindered Citigroup's (C) Q4 NII growth. Also, the likelihood of a higher expense base is concerning. Nonetheless, green shoots in IB business is likely to aid results.
0
Jobs +216K, Unemployment 3.7%: Better than Expected
https://www.zacks.com/stock/news/2206364/jobs-216k-unemployment-3-7-better-than-expected?cid=CS-ZC-FT-ahead_of_wall_street-2206364
Jan 05, 2024 - If you're looking for data that will allow the Fed to put some slack in interest rates near-term, these numbers are a disappointment.
0